Detalhe da pesquisa
1.
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
Hepatology
; 77(1): 65-76, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491432
2.
Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.
Neuroendocrinology
; 112(8): 733-743, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592743
3.
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Gastric Cancer
; 24(4): 913-925, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33945049
4.
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
Br J Cancer
; 114(2): 138-45, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26784122
5.
Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer.
Chin J Cancer Res
; 28(6): 579-588, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28174486
6.
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhonghua Zhong Liu Za Zhi
; 36(3): 223-7, 2014 Mar.
Artigo
em Zh
| MEDLINE | ID: mdl-24785285
7.
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
Int Immunopharmacol
; 137: 112364, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38865752
8.
Helicobacter pylori and immunotherapy for gastrointestinal cancer.
Innovation (Camb)
; 5(2): 100561, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38379784
9.
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
EClinicalMedicine
; 68: 102415, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235421
10.
Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer.
J Immunother Cancer
; 12(2)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302415
11.
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.
Nat Med
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38830992
12.
Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study.
Front Oncol
; 13: 1285478, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38090496
13.
Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
J Cancer Res Clin Oncol
; 149(2): 779-789, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35166929
14.
Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Cancer Med
; 12(9): 10704-10714, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37081722
15.
Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor.
Front Endocrinol (Lausanne)
; 13: 947998, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36465662
16.
Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Clin Colorectal Cancer
; 21(3): e152-e161, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216918
17.
A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor.
Front Pharmacol
; 13: 833583, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35935841
18.
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Nat Med
; 28(6): 1189-1198, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534566
19.
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
J Clin Oncol
; 39(7): 748-756, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33417481
20.
Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden.
Cancer Commun (Lond)
; 40(12): 746-751, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33230973